Literature DB >> 21102433

Glioblastoma stem-like cells give rise to tumour endothelium.

Rong Wang1, Kalyani Chadalavada, Jennifer Wilshire, Urszula Kowalik, Koos E Hovinga, Adam Geber, Boris Fligelman, Margaret Leversha, Cameron Brennan, Viviane Tabar.   

Abstract

Glioblastoma (GBM) is among the most aggressive of human cancers. A key feature of GBMs is the extensive network of abnormal vasculature characterized by glomeruloid structures and endothelial hyperplasia. Yet the mechanisms of angiogenesis and the origin of tumour endothelial cells remain poorly defined. Here we demonstrate that a subpopulation of endothelial cells within glioblastomas harbour the same somatic mutations identified within tumour cells, such as amplification of EGFR and chromosome 7. We additionally demonstrate that the stem-cell-like CD133(+) fraction includes a subset of vascular endothelial-cadherin (CD144)-expressing cells that show characteristics of endothelial progenitors capable of maturation into endothelial cells. Extensive in vitro and in vivo lineage analyses, including single cell clonal studies, further show that a subpopulation of the CD133(+) stem-like cell fraction is multipotent and capable of differentiation along tumour and endothelial lineages, possibly via an intermediate CD133(+)/CD144(+) progenitor cell. The findings are supported by genetic studies of specific exons selected from The Cancer Genome Atlas, quantitative FISH and comparative genomic hybridization data that demonstrate identical genomic profiles in the CD133(+) tumour cells, their endothelial progenitor derivatives and mature endothelium. Exposure to the clinical anti-angiogenesis agent bevacizumab or to a γ-secretase inhibitor as well as knockdown shRNA studies demonstrate that blocking VEGF or silencing VEGFR2 inhibits the maturation of tumour endothelial progenitors into endothelium but not the differentiation of CD133(+) cells into endothelial progenitors, whereas γ-secretase inhibition or NOTCH1 silencing blocks the transition into endothelial progenitors. These data may provide new perspectives on the mechanisms of failure of anti-angiogenesis inhibitors currently in use. The lineage plasticity and capacity to generate tumour vasculature of the putative cancer stem cells within glioblastoma are novel findings that provide new insight into the biology of gliomas and the definition of cancer stemness, as well as the mechanisms of tumour neo-angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21102433     DOI: 10.1038/nature09624

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  31 in total

1.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Authors:  Mitomu Kioi; Hannes Vogel; Geoffrey Schultz; Robert M Hoffman; Griffith R Harsh; J Martin Brown
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

2.  Endothelial tubes assemble from intracellular vacuoles in vivo.

Authors:  Makoto Kamei; W Brian Saunders; Kayla J Bayless; Louis Dye; George E Davis; Brant M Weinstein
Journal:  Nature       Date:  2006-06-21       Impact factor: 49.962

3.  Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.

Authors:  D Lyden; K Hattori; S Dias; C Costa; P Blaikie; L Butros; A Chadburn; B Heissig; W Marks; L Witte; Y Wu; D Hicklin; Z Zhu; N R Hackett; R G Crystal; M A Moore; K A Hajjar; K Manova; R Benezra; S Rafii
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

4.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Authors:  Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

Review 5.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

Review 6.  AC133/CD133/Prominin-1.

Authors:  Sergey V Shmelkov; Ryan St Clair; David Lyden; Shahin Rafii
Journal:  Int J Biochem Cell Biol       Date:  2005-04       Impact factor: 5.085

Review 7.  Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.

Authors:  Nikolaos A Dallas; Shaija Samuel; Ling Xia; Fan Fan; Michael J Gray; Sherry J Lim; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

8.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.

Authors:  Rose Du; Kan V Lu; Claudia Petritsch; Patty Liu; Ruth Ganss; Emmanuelle Passegué; Hanqiu Song; Scott Vandenberg; Randall S Johnson; Zena Werb; Gabriele Bergers
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

10.  Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.

Authors:  Cameron Brennan; Hiroyuki Momota; Dolores Hambardzumyan; Tatsuya Ozawa; Adesh Tandon; Alicia Pedraza; Eric Holland
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

View more
  506 in total

1.  VEGF is essential for the growth and migration of human hepatocellular carcinoma cells.

Authors:  Lei Zhang; Jia-Ning Wang; Jun-Ming Tang; Xia Kong; Jian-Ye Yang; Fei Zheng; Ling-Yun Guo; Yong-Zhang Huang; Li Zhang; Lin Tian; Shu-Fen Cao; Chang-Hai Tuo; Hong-Li Guo; Shi-You Chen
Journal:  Mol Biol Rep       Date:  2011-12-10       Impact factor: 2.316

2.  Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.

Authors:  Jan-Karl Burkhardt; Howard Riina; Benjamin J Shin; Paul Christos; Kartik Kesavabhotla; Christoph P Hofstetter; Apostolos John Tsiouris; John A Boockvar
Journal:  World Neurosurg       Date:  2011-11-21       Impact factor: 2.104

Review 3.  Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer.

Authors:  Robert Strauss; Petra Hamerlik; André Lieber; Jiri Bartek
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

Review 4.  Intra-arterial chemotherapy for malignant gliomas: a critical analysis.

Authors:  J-K Burkhardt; H A Riina; B J Shin; J A Moliterno; C P Hofstetter; J A Boockvar
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

Review 5.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

6.  Cancer: Tumour stem cells switch sides.

Authors:  Victoria L Bautch
Journal:  Nature       Date:  2010-12-09       Impact factor: 49.962

Review 7.  CD133-targeted niche-dependent therapy in cancer: a multipronged approach.

Authors:  Anthony B Mak; Caroline Schnegg; Chiou-Yan Lai; Subrata Ghosh; Moon Hee Yang; Jason Moffat; Mei-Yu Hsu
Journal:  Am J Pathol       Date:  2014-02-28       Impact factor: 4.307

8.  Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.

Authors:  Rong Shao; Ralph Francescone; Nipaporn Ngernyuang; Brooke Bentley; Sherry L Taylor; Luis Moral; Wei Yan
Journal:  Carcinogenesis       Date:  2013-11-26       Impact factor: 4.944

Review 9.  Glioblastoma stem cells: Molecular characteristics and therapeutic implications.

Authors:  Nermin Sumru Bayin; Aram Sandaldjian Modrek; Dimitris George Placantonakis
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 10.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.